Poxel’s Pioglitazone Formulation Meets Key Endpoints In Phase II NASH Study

 
• By Joseph Haas
  
Tough choice
Poxel now must make a decision on which Phase II NASH drug to take forward • Source: Shutterstock

More from Clinical Trials

More from R&D